Dr Jonathan Krell, Consultant Oncologist
Dr Jonathan Krell
Consultant Oncologist
Recommendations for Dr Krell
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
About Dr Jonathan Krell
GMC number: 6075165
Year qualified: 2003
Place of primary qualification: University of Leeds
Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers. He has a particular interest in cancer genetics and hereditary malignancies, especially concerning BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers.
Dr Krell qualified in medicine at Leeds University Medical School, where he also earned a first-class honours degree in Pharmacology. He completed his junior doctor positions at St James' Hospital in Leeds and St Thomas' Hospital in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.
His PhD work, funded by the Medical Research Council, investigated the interplay between genetic mutations, DNA damage, and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College. This team aims to overcome resistance to current anti-cancer agents in ovarian and breast cancer.
Dr Krell has published more than 100 peer-reviewed papers in academic journals and regularly presents his research at national and international conferences.
Dr Krell's dedication to advancing cancer treatment and his extensive research make him a highly respected figure in the field of oncology.
Areas of expertise
- Breast cancer
- Gynaecological cancer
- Urological cancer
Professional memberships
Articles by Dr Jonathan Krell
The clinical use of circulating tumor cells (ctcs) enumeration for staging of metastatic breast cancer (mbc): international expert consensus paper
Correction: does molecular profiling of tumors using the caris molecular intelligence platform improve outcomes for cancer patients?
Correction: assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy
Author correction: tgf-β induces mir-100 and mir-125b but blocks let-7a through lin28b controlling pdac progression
Size-exclusion chromatography as a technique for the investigation of novel extracellular vesicles in cancer
Correction: the benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas
Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden